|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Mutations in an auxin receptor homolog AFB5 and in SGT1bconfer resistance to synthetic picolinate auxins and not to 2,4-D or IAA in Arabidopsis显示文摘 | WALSH T A NEAL R MERLO A O HONMA M HICKS G R WOLFF K MATSUMURA W DAVIES J P | 2006 | Plant Physiology2006，142，： | 1 |
| 2 | Mutations in an Auxin Receptor Homolog AFB5 and in SGTlb Confer Resistance to Synthetic Picolinate Auxins and not to 2,4-D or IAA in Arabidopsis 显示文摘 | WALSH T A NEAL R MERLO A O | 2006 | Plant Physiology2006，142，： | 1 |
| 3 | Mutations in an auxin receptor homolog AFB5 and in SC-T1 b confer resistance to synthetic picolinate auxins and not to 2, 4-dichlorophenoxyacetic acid or indole-3-acetic acid in Arabidopsis 显示文摘 | Walsh T A Neal R Merlo A O | 2006 | Plant Physiol2006，142，： | 1 |
| 4 | Acta Non Verba? The Role of Customer Participation and Word of Mouth in the Relationship Between Service Firms' Customer Satisfaction and Sales Performance 显示文摘 | EISINGERICH A B AUH S MERLO O | 2014 | Journal of Service Research2014，17，1： | 1 |
| 5 | Massage in hypertrophic scars 显示文摘 | Patifio O Novick C Merlo A | 1999 | J Burn Care Rehabil1999，20，3： | 1 |
| 6 | Characterization of a genomic sequence coding for potato multicystatin, and eight-domain cysteine proteinase inhibitor 显示文摘 | WALDRON C WEGRICH L M MERLO P A O | 1993 | Plant Molecular Biology1993，23，4： | 1 |
| 7 | Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA 0-D-Phel-Tyr3-octreotide (DOTATOC):a pilot study in human gliomas显示文摘 | Merlo A Hausmann O Wasner M | 1999 | Clin Cancer Res1999，5，5： | 1 |
| 8 | Massage in hypertrophic scars 显示文摘 | PATINO O NOVICK C MERLO A | 1999 | J Burn Care Rehabil1999，20，3： | 1 |
| 9 | Massage in hypertrophic scars 显示文摘 | Patino O Novick C Merlo A | 1999 | J Burn Care Rehabil1999，20，2： | 1 |
| 10 | Massage in hypertrophic scars显示文摘 | Patino O Novick C Merlo A | 1999 | J Bum Care Rehabil1999，20，2： | 1 |
| 11 | Effects of exercise training on endothelial progenitor cells in patients with chronic heart failure 显示文摘 | Sarto P Balducci E Balconi G Fiordaliso F Merlo L Tuzzato G PappagaUo GL Frigato N Zanocco A Forestieri C Azzarello G Mazzucco A Valenti MT Alborino F Noventa D Vinante O Pascotto P Sartore S Dejana E Latini R | 2007 | J Card Fail2007，13，9： | 1 |
| 12 | Power and Marketing 显示文摘 | Merlo O Whitwell G J Lukas B A | 2004 | Journal of Strategic Marketing2004，12，4： | 1 |
| 13 | 5' CpG island methyIation is associated with transcrfptionsl silencing of the tumour suppressor p16/ CDKN2/MTS1 in human cancers显示文摘 | Merlo A Herman J O Mao L et &l | 1995 | Nat Med1995，1，7： | 1 |
| 14 | Acta non verba?The role of customer participation and word of mouth in the relationship between service firms’customer satisfaction and sales performance显示文摘 | Eisingerich A B Auh S Merlo O | 2014 | Journal of Service Research2014，17，1： | 1 |
| 15 | Bispecific sigma-1 receptor antagonism and mu-opioid receptor partial agonism:WLB-73502,an analgesic with improved efficacy and safety profile compared to strong opioids显示文摘Opioids are the most effective painkillers,but their benefit-risk balance often hinder their therapeutic use.WLB-73502 is a dual,bispecific compound that binds sigma-1(S1R)and mu-opioid(MOR)receptors.WLB-73502 is an antagonist at the S1R.It behaved as a partial MOR agonist at the G-protein pathway and produced no/unsignificantβ-arrestin-2 recruitment,thus demonstrating low intrinsic efficacy on MOR at both signalling pathways.Despite its partial MOR agonism,WLB-73502exerted full antinociceptive efficacy,with potency superior to morphine and similar to oxycodone against nociceptive,inflammatory and osteoarthritis pain,and superior to both morphine and oxycodone against neuropathic pain.WLB-73502 crosses the blood-brain barrier and binds brain S1R and MOR to an extent consistent with its antinociceptive effect.Contrary to morphine and oxycodone,tolerance to its antinociceptive effect did not develop after repeated 4-week administration.Also,contrary to opioid comparators,WLB-73502 did not inhibit gastrointestinal transit or respiratory function in rats at doses inducing full efficacy,and it was devoid of proemetic effect(retching and vomiting)in ferrets at potentially effective doses.WLB-73502 benefits from its bivalent S1R antagonist and partial MOR agonist nature to provide an improved antinociceptive and safety profile respect to strong opioid therapy. | Alba Vidal-Torres Begoña Fernández-Pastor Mónica García Eva Ayet Anna Cabot Javier Burgueño Xavier Monroy Bertrand Aubel Xavier Codony Luz Romero Rosalía Pascual Maria Teresa Serafini Gregorio Encina Carmen Almansa Daniel Zamanillo Manuel Merlos JoséMiguel Vela | 2023 | Acta Pharmaceutica Sinica B2023，13，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员